Is fosfomycin effective against Staphylococcus aureus, including methicillin‑susceptible and methicillin‑resistant strains?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Fosfomycin Cover Staph Aureus?

Fosfomycin has in vitro activity against Staphylococcus aureus (both MSSA and MRSA), but it is NOT recommended as monotherapy and is NOT included in standard treatment guidelines for S. aureus infections.

Key Evidence from FDA Labeling and Guidelines

The FDA label for fosfomycin 1 notably does NOT list Staphylococcus aureus among the organisms for which fosfomycin is indicated for clinical use. The label only lists:

  • Enterococcus faecalis (gram-positive)
  • Escherichia coli (gram-negative)

This is critical because the FDA approval is specifically for uncomplicated urinary tract infections, where fosfomycin achieves high urinary concentrations (706 mcg/mL within 2-4 hours) 1.

What the IDSA Guidelines Say

The comprehensive 2011 IDSA guidelines for MRSA treatment 2 provide detailed recommendations for every major S. aureus infection type (skin/soft tissue, bacteremia, endocarditis, pneumonia, osteomyelitis, CNS infections) and fosfomycin is conspicuously absent from all treatment recommendations.

Standard recommended agents include:

  • Vancomycin (first-line for MRSA)
  • Daptomycin (alternative for MRSA)
  • Linezolid (alternative for MRSA)
  • Cefazolin or anti-staphylococcal penicillins (for MSSA) 3

In Vitro Activity vs. Clinical Use

While research shows fosfomycin has in vitro activity against S. aureus:

  • Susceptibility rates of 87.9% for MRSA in pooled studies 4
  • 90%+ susceptibility in multiple surveillance studies 5

However, there is a critical caveat: Fosfomycin readily develops resistance when used as monotherapy 5. Resistant mutants emerge rapidly, which is why it should only be considered in combination therapy.

When Fosfomycin Might Be Considered (Off-Label)

Fosfomycin may have a role as salvage combination therapy in specific refractory situations:

Clinical Evidence for Combination Therapy:

  • Daptomycin + fosfomycin: Most studied combination with synergistic activity in vitro 6, 7

    • Case series showed 81% success rate for severe gram-positive infections 6
    • Successfully treated endocarditis in small case series 7
  • For persistent MRSA bacteremia after standard therapy failure 8:

    • Three case reports showed clearance when fosfomycin added to DAP or VCM
    • Bacteremia cleared 6-8 days after fosfomycin addition

Important Limitations:

  • A 2025 meta-analysis of RCTs 9 found fosfomycin combination therapy for S. aureus bacteremia/endocarditis did NOT significantly improve mortality (RR 0.85; 95% CI 0.28-2.52) or persistent bacteremia
  • Higher rates of adverse events leading to discontinuation (though not statistically significant)
  • Most positive data comes from case series and in vitro studies, not high-quality RCTs

Practical Clinical Algorithm

For routine S. aureus infections:

  • ❌ Do NOT use fosfomycin as first-line, second-line, or even third-line therapy
  • ✅ Use guideline-recommended agents (vancomycin, daptomycin, linezolid for MRSA; cefazolin for MSSA) 2, 3

For refractory/persistent S. aureus bacteremia despite:

  1. Adequate source control
  2. Appropriate standard antibiotics (vancomycin or daptomycin)
  3. Confirmed susceptibility testing

Then consider:

  • High-dose daptomycin (10 mg/kg) + fosfomycin as salvage therapy 8
  • Never use fosfomycin alone due to rapid resistance development 5
  • Ensure susceptibility testing confirms fosfomycin activity (MIC ≤64 mcg/mL)

Critical Pitfalls to Avoid

  1. Do not use fosfomycin monotherapy for any systemic S. aureus infection—resistance develops within days 5

  2. Do not assume urinary concentrations translate to systemic efficacy—fosfomycin achieves high urinary levels but systemic penetration is limited 1

  3. Do not use fosfomycin as empiric therapy—it is not guideline-supported and should only be considered after consultation with infectious disease specialists for salvage situations

  4. Do not overlook source control—adding fosfomycin will not compensate for inadequate drainage or retained hardware 2

Bottom line: While fosfomycin has microbiologic activity against S. aureus, it lacks clinical validation, FDA approval, and guideline support for this indication. Reserve it only for desperate salvage situations in combination therapy after infectious disease consultation.

References

Research

Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci.

Enfermedades infecciosas y microbiologia clinica (English ed.), 2019

Research

Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2024

Related Questions

Is fosfomycin appropriate for treating methicillin‑resistant coagulase‑negative Staphylococcus (MRCoNS) infections, and what are the recommended dosing regimens for urinary and systemic infections?
Is fosfomycin appropriate for treating a methicillin‑resistant coagulase‑negative Staphylococcus (MRCoNS) infection that is susceptible to fosfomycin, and what dosing regimen should be used?
Can fosfomycin be combined with doxycycline for treating methicillin‑resistant coagulase‑negative Staphylococcus (MRCoNS) infections?
What is the best treatment for a patient with a malodorous coccyx wound, containing small amounts of pus, and culture results showing many polymorphonuclear leukocytes (PMNs), red blood cells (RBCs), squamous epithelial cells, and Gram-positive cocci?
What is the recommended treatment for a patient with a prosthetic heart valve infected with Methicillin-resistant Staphylococcus aureus (MRSA)?
What is the most effective approach to mitigate oxidative stress associated with stimulant use?
What is the new preferred term for treatment‑resistant depression (TRD)?
After how many cycles of FOLFOX (folinic acid, fluorouracil, oxaliplatin) should restaging imaging be performed?
Can atypical lymphoid cells with blastoid features and associated thrombocytopenia be caused by a viral infection?
Please interpret the urinalysis results showing low‑normal specific gravity, pH 7.5, clear yellow urine, negative protein, glucose, ketones, blood, bilirubin, urobilinogen, and nitrite, 3+ leukocyte esterase, microscopic white blood cells 0‑5 per high‑power field, no red blood cells, and moderate bacteria.
In a patient with chronic kidney disease stage 4, can oxycodone be prescribed as needed for pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.